Cancer Clinical Trial
Official title:
A Multi-center, Open-label, Randomized, Phase 2 Clinical Trial Evaluating Safety and Efficacy of FOLFIRI With Either Panitumumab or Bevacizumab as Second-Line Treatment in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Tumors
Verified date | September 2018 |
Source | Amgen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a multi-center, open-label, randomized, phase 2, two-arm clinical trial to be conducted in the United States. Approximately 210 eligible KRAS wild-type expressing metastatic colorectal cancer subjects who have failed first-line oxaliplatin-based chemotherapy (with at least 4 doses of oxaliplatin-based chemotherapy) with at least 4 doses of bevacizumab (failure is defined as toxicity due to oxaliplatin-based chemotherapy or progression of disease on first-line treatment) will be randomized in a 1:1 ratio to receive either a once-every-two-weeks (Q2W) FOLFIRI regimen plus panitumumab 6 mg/kg or a Q2W FOLFIRI regimen plus bevacizumab (either 5 mg/kg or 10 mg/kg, depending on physician choice and institutional standard of care).
Status | Completed |
Enrollment | 266 |
Est. completion date | April 1, 2013 |
Est. primary completion date | May 10, 2012 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria - Diagnosis of metastatic adenocarcinoma of the colon or rectum that cannot, in the opinion of the investigator, be cured by surgical resection at the time of randomization - Wild-type KRAS expressing mCRC from the primary tumor or metastasis. - Failure of prior first-line oxaliplatin-based chemotherapy with bevacizumab (at least four therapeutic doses of oxaliplatin-based chemotherapy and bevacizumab) for mCRC. - At least one uni-dimensionally measurable lesion per modified RECIST criteria. - Cooperative Oncology Group (ECOG) performance status of 0 or 1 - Man or woman 18 years of age or older - Hematology, chemistry, coagution, metabolic functions within normal or protocol-defined limits Exclusion Criteria - Previous irinotecan, anti-EGFr therapy (eg, cetuximab, panitumumab, erlotinib, gefitinib, lapatinib) or vaccine for the treatment of mCRC - Radiotherapy = 14 days before randomization - Evidence of central nervous system (CNS) metastases - Unresolved toxicities from prior anti-cancer therapy that, in the opinion of the investigator, precludes subject from participation - History of other invasive primary cancer, except: - Curatively resected or treated non-melanomatous skin cancer - Curatively treated cervical carcinoma in situ - Other primary solid tumor treated curatively and no treatment administered = 2 years before randomization and, in the investigator's opinion, it is unlikely that there will be a recurrence = 2 years post randomization Medications - C hronic daily treatment (as determined by the investigator) with aspirin (> 325 mg/day) or non steroidal anti inflammatory agents known to inhibit platelet function - Infection requiring a course of systemic anti-infectives that was completed = 14 days before randomization (exception can be made at the judgment of the investigator for oral treatment of an uncomplicated urinary tract infection [UTI]) - Subjects concurrently receiving any investigational agent or therapy = 30 days before randomization General: - Significant cardiovascular risk as defined by the protocol - History of peripheral arterial ischemia = 24 weeks before randomization (subjects with brief, reversible, exercise-induced claudication are eligible) - History of visceral arterial ischemia = 24 weeks before randomization - Significant bleeding risk: - Major surgical procedure, open biopsy, or significant traumatic injury = 28 days before randomization - Anticipation of need for major surgical procedures during the course of the study - C ore biopsy or other minor procedure, excluding placement of a vascular access device = 7 days before randomization - A ny significant bleeding that is not related to the primary colon tumor = 24 weeks before randomization - P re-existing bleeding diathesis or coagulopathy with the exception of well-controlled chronic anticoagulation therapy - Serious or non-healing wounds, skin ulcers, or unhealed bone fractures - Gastroduodenal ulcer(s) determined by endoscopy to be active or uncontrolled gastrointestinal ulcer = 28 days before randomization - History of interstitial lung disease (eg, pneumonitis or pulmonary fibrosis) or evidence of interstitial lung disease on baseline chest x-ray (CXR) or computed tomography (CT) scan - Clinically significant ascites - Subjects known to be human immunodeficiency virus (HIV) positive or known to have chronic or active hepatitis B or C infection - Men and women of childbearing potential (women who are post-menopausal < 52 weeks, not surgically sterilized, or not abstinent) who do not consent to use adequate contraception (according to institutional standard of care) during the course of the study and after the last date of receiving second-line treatment (24 weeks for women, 4 weeks for men) - Women who test positive for serum or urine pregnancy test = 72 hours before randomization or are breast-feeding - Subjects allergic to any component that is part of the treatment regimen |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Amgen |
Hecht JR, Cohn A, Dakhil S, Saleh M, Piperdi B, Cline-Burkhardt M, Tian Y, Go WY. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2015 Jun;14(2):72-80. doi: 10.1016/j.clcc.2014.12.009. Epub 2015 Jan 8. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-free Survival (PFS) | Progression-free survival is defined as time from the date of randomization to the date of first progression per modified RECIST version 1.0 (based on central review of the radiographic scans), or death within 60 days after the last evaluable tumor assessment or randomization date (whichever is later). | From randomization up to 65 months. | |
Secondary | Overall Survival | Overall survival is defined as time from the date of randomization to the date of death due to any cause. Subjects who have not died or are lost to follow-up at the analysis cutoff date will be censored at their last contact date. | From randomization up to 65 months. | |
Secondary | Objective Response Rate | Objective response rate is defined as incidence of either a confirmed complete response (CR) or partial response (PR) on study up to starting a new anti-tumor therapy and will be based on modified RECIST version 1.0 (responder) by central assessment. | From randomization up to 65 months. | |
Secondary | Time to Response | Time to response is defined as time from the date of randomization to the date of first confirmed objective response | From randomization up to 65 months. | |
Secondary | Time to Progression | Time to progression is defined as time from the date of randomization to the date of radiographic disease progression per modified RECIST version 1.0 (per central assessment). | From randomization up to 65 months. | |
Secondary | Disease Control | Disease control is defined as incidence of objective response or stable disease on study up to starting a new anti-tumor therapy. | From randomization up to 65 months. | |
Secondary | Duration of Response | Duration of response is defined as time from first confirmed objective response to disease progression per modified RECIST version 1.0 (by central assessment). | From randomization up to 65 months. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|